Related references
Note: Only part of the references are listed.TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase
Chandtip Chandhasin et al.
ANTI-CANCER DRUGS (2023)
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Jing Yang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)
HDAC2 as a target for developing anti-cancer drugs
Hyein Jo et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2023)
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
Valeria Santini et al.
ADVANCES IN THERAPY (2022)
The emerging roles of circRNAs in cancer and oncology
Lasse S. Kristensen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Effect of aberrant DNA methylation on cancer stem cell properties
Zeinab Mazloumi et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2022)
A lncRNA signature associated with tumor immune heterogeneity predicts distant metastasis in locoregionally advanced nasopharyngeal carcinoma
Ye-Lin Liang et al.
NATURE COMMUNICATIONS (2022)
P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease
Iman Imtiyaz Ahmed Juvale et al.
HELIYON (2022)
LncRNAs in tumor metabolic reprogramming and immune microenvironment remodeling
Jiecheng Yang et al.
CANCER LETTERS (2022)
Epigenetic tumor heterogeneity in the era of single-cell profiling with nanopore sequencing
Yohannis Wondwosen Ahmed et al.
CLINICAL EPIGENETICS (2022)
Resetting the epigenome: Methylation dynamics in cancer stem cells
Aiendrila Roy et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)
Drug resistance in colorectal cancer: An epigenetic overview
Maochao Luo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2021)
Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy
Mengjiao Zhou et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
The epigenetic basis of cellular heterogeneity
Benjamin Carter et al.
NATURE REVIEWS GENETICS (2021)
MicroRNA-155 contributes to plexiform neurofibroma growth downstream of MEK
Youjin Na et al.
ONCOGENE (2021)
The DNA methylation-regulated MCTP1 activates the drug-resistance of esophageal cancer cells
Lingsuo Kong et al.
Aging-US (2021)
Structure and Function of Chromatin Remodelers
Alexis A. Reyes et al.
JOURNAL OF MOLECULAR BIOLOGY (2021)
Non-coding RNA in cancer
Huiwen Yan et al.
NON-CODING GENOME (2021)
An Epigenetic Perspective on Intra-Tumour Heterogeneity: Novel Insights and New Challenges from Multiple Fields
Sven Beyes et al.
CANCERS (2021)
Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Iris Lodewijk et al.
CLINICAL EPIGENETICS (2021)
Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer
Patricia Le et al.
CANCERS (2021)
MicroRNA: A signature for cancer progression
Bashdar Mahmud Hussen et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer
Zhangxiang Zhao et al.
ONCOGENE (2021)
Navigating the DNA methylation landscape of cancer
Atsuya Nishiyama et al.
TRENDS IN GENETICS (2021)
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
Chunhong Hu et al.
CLINICAL EPIGENETICS (2021)
Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential
Ya-Nan Pi et al.
FRONTIERS IN IMMUNOLOGY (2021)
miR-155-5p increases the sensitivity of liver cancer cells to adriamycin by regulating ATG5-mediated autophagy
Qiu Yu et al.
NEOPLASMA (2021)
Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells
Xuan Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
The emerging role of epigenetic therapeutics in immuno-oncology
Michael J. Topper et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Histone Lysine Methylation Dynamics Control EGFR DNA Copy-Number Amplification
Thomas L. Clarke et al.
CANCER DISCOVERY (2020)
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
Xinyi Zhang et al.
MOLECULAR CANCER (2020)
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
David S. Hong et al.
BRITISH JOURNAL OF CANCER (2020)
Non-coding Natural Antisense RNA: Mechanisms of Action in the Regulation of Target Gene Expression and Its Clinical Implications
Tominori Kimura
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2020)
MicroRNA (miR) dysregulation during Helicobacter pylori-induced gastric inflammation and cancer development: critical importance of miR-155
Christian Prinz et al.
Oncotarget (2020)
Long Non-coding RNA EPIC1 Promotes Cell Proliferation and Motility and Drug Resistance in Glioma
Jianjiao Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
Role of DNA Methylation in the Resistance to Therapy in Solid Tumors
Susana Romero-Garcia et al.
FRONTIERS IN ONCOLOGY (2020)
Chromatin-modifying drugs and metabolites in cell fate control
Ziyue Yao et al.
CELL PROLIFERATION (2020)
Modified Nucleic Acids: Expanding the Capabilities of Functional Oligonucleotides
Steven Ochoa et al.
MOLECULES (2020)
Drug Resistance in Cancer Therapy and the Role of Epigenetics
Takeshi Asano
JOURNAL OF NIPPON MEDICAL SCHOOL (2020)
The tumor suppressor microRNA let-7 inhibits human LINE-1 retrotransposition
Pablo Tristan-Ramos et al.
NATURE COMMUNICATIONS (2020)
miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial
Gayathri Anandappa et al.
CLINICAL CANCER RESEARCH (2019)
LncRNA ANRIL affects the sensitivity of ovarian cancer to cisplatin via regulation of let-7a/HMGA2 axis
Jin-Tian Miao et al.
BIOSCIENCE REPORTS (2019)
Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism
Mengyuan Huang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Long Non-Coding RNA in the Pathogenesis of Cancers
Yujing Chi et al.
CELLS (2019)
The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer: a systematic review with meta-analysis
Chuchu Shao et al.
BMC CANCER (2019)
The Role of Non-coding RNAs in Oncology
Frank J. Slack et al.
CELL (2019)
Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy
Alison Hirukawa et al.
CELL REPORTS (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Role of miRNAs in immune responses and immunotherapy in cancer
Maria Angelica Cortez et al.
GENES CHROMOSOMES & CANCER (2019)
Structural transition of the nucleosome during chromatin remodeling and transcription
Wataru Kobayashi et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2019)
Prognostic and Predictive Epigenetic Biomarkers in Oncology
Katarzyna Kaminska et al.
MOLECULAR DIAGNOSIS & THERAPY (2019)
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Yuan Cheng et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Lung cancer epigenetics: From knowledge to applications
Michael Duruisseaux et al.
SEMINARS IN CANCER BIOLOGY (2018)
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Jia Yu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy
Adam J. Wolpaw et al.
TRENDS IN CELL BIOLOGY (2018)
Therapeutic Targeting of Long Non-Coding RNAs in Cancer
Gayatri Arun et al.
TRENDS IN MOLECULAR MEDICINE (2018)
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Jens C. Hahne et al.
FRONTIERS IN ONCOLOGY (2018)
Precise Small Molecule Degradation of a Noncoding RNA Identifies Cellular Binding Sites and Modulates an Oncogenic Phenotype
Yue Li et al.
ACS CHEMICAL BIOLOGY (2018)
MiR-34 inhibits polycomb repressive complex 2 to modulate chaperone expression and promote healthy brain aging
Jason R. Kennerdell et al.
NATURE COMMUNICATIONS (2018)
Histone modifications and their role in epigenetics of atopy and allergic diseases
Bilal Alaskhar Alhamwe et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2018)
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Roisin M. Connolly et al.
CLINICAL CANCER RESEARCH (2017)
lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study
Paolo Martini et al.
CLINICAL CANCER RESEARCH (2017)
Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics
Maria A. Smolle et al.
FEBS JOURNAL (2017)
Ascorbate regulates haematopoietic stem cell function and leukaemogenesis
Michalis Agathocleous et al.
NATURE (2017)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rajesha Rupaimoole et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Epigenetic plasticity and the hallmarks of cancer
William A. Flavahan et al.
SCIENCE (2017)
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Mark A. Dawson
SCIENCE (2017)
LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194
Jihong An et al.
ONCOTARGETS AND THERAPY (2017)
MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA
Amr A. Al-Haidari et al.
ONCOTARGET (2017)
Long non-coding RNA MIAT promotes breast cancer progression and functions as ceRNA to regulate DUSP7 expression by sponging miR-155-5p
Tian Luan et al.
ONCOTARGET (2017)
Long Noncoding RNA and Cancer: A New Paradigm
Arunoday Bhan et al.
CANCER RESEARCH (2017)
Clinical and biological effects of demethylating agents on solid tumours - A systematic review
J. F. Linnekamp et al.
CANCER TREATMENT REVIEWS (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance
Brian B. Liau et al.
CELL STEM CELL (2017)
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma
Li-Si Zeng et al.
AGING-US (2016)
Let-7 inhibits self-renewal of hepatocellular cancer stem-like cells through regulating the epithelial-mesenchymal transition and the Wnt signaling pathway
Bin Jin et al.
BMC CANCER (2016)
HIF-miR-215-KDM1B promotes glioma-initiating cell adaptation to hypoxia
Jing Hu et al.
CELL CYCLE (2016)
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors
Manuela Terranova-Barberio et al.
IMMUNOTHERAPY (2016)
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications
Lisa Pleyer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Andrew P. Feinberg et al.
NATURE REVIEWS GENETICS (2016)
Targeting the cancer epigenome for therapy
Peter A. Jones et al.
NATURE REVIEWS GENETICS (2016)
Design of a small molecule against an oncogenic noncoding RNA
Sai Pradeep Velagapudi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Histone Modifications and Cancer
James E. Audia et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Epigenetic Determinants of Cancer
Stephen B. Baylin et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2016)
Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
Babette Haven et al.
ELIFE (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects
Lan-Xiang Wu et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Deregulation of miR-126 expression in colorectal cancer pathogenesis and its clinical significance
Faeza Ebrahimi et al.
EXPERIMENTAL CELL RESEARCH (2015)
Toward understanding and exploiting tumor heterogeneity
Ash A. Alizadeh et al.
NATURE MEDICINE (2015)
The promise and failures of epigenetic therapies for cancer treatment
Pasano Bojang et al.
CANCER TREATMENT REVIEWS (2014)
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators
Hui Yang et al.
FASEB JOURNAL (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Bertrand Coiffier et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Hariharan Easwaran et al.
MOLECULAR CELL (2014)
Epigenetic Control of Immunity
Meinrad Busslinger et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
DNA methyltransferases: a novel target for prevention and therapy
Dharmalingam Subramaniam et al.
FRONTIERS IN ONCOLOGY (2014)
Cancers with wrong HATs: the impact of acetylation
Vincenzo Di Cerbo et al.
BRIEFINGS IN FUNCTIONAL GENOMICS (2013)
Histone Acetylation Regulates Intracellular pH
Matthew A. McBrian et al.
MOLECULAR CELL (2013)
Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells
Kathryn Blaschke et al.
NATURE (2013)
The causes and consequences of genetic heterogeneity in cancer evolution
Rebecca A. Burrell et al.
NATURE (2013)
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Hui Ling et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
DNA Methylation and Its Basic Function
Lisa D. Moore et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
Jueng Soo You et al.
CANCER CELL (2012)
Epigenetic Resensitization to Platinum in Ovarian Cancer
Daniela Matei et al.
CANCER RESEARCH (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer
Gary C. Hon et al.
GENOME RESEARCH (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
被撤回的出版物: Lysyl Oxidase-like 2 Deaminates Lysine 4 in Histone H3 (Retracted article. See vol. 63, pg. 180, 2016)
Nicolas Herranz et al.
MOLECULAR CELL (2012)
Histone deacetylases and cancer
Bruna Barneda-Zahonero et al.
MOLECULAR ONCOLOGY (2012)
Identification of Combinatorial Patterns of Post-Translational Modifications on Individual Histones in the Mouse Brain
Ry Y. Tweedie-Cullen et al.
PLOS ONE (2012)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
Phase 1b-2a Study to Reverse Platinum Resistance Through Use of a Hypomethylating Agent, Azacitidine, in Patients With Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Siqing Fu et al.
CANCER (2011)
Non-coding RNAs as regulators of gene expression and epigenetics
Minna U. Kaikkonen et al.
CARDIOVASCULAR RESEARCH (2011)
Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification
Minjia Tan et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Epigenetic Modifications Basic Mechanisms and Role in Cardiovascular Disease
Diane E. Handy et al.
CIRCULATION (2011)
Epigenetics: Principles and Practice
James P. Hamilton
DIGESTIVE DISEASES (2011)
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2011)
Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
Rosalyn A. Juergens et al.
CANCER DISCOVERY (2011)
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)
L. R. Molife et al.
ANNALS OF ONCOLOGY (2010)
A Phase 1 and Pharmacodynamic Study of Decitabine in Combination With Carboplatin in Patients With Recurrent, Platinum-Resistant, Epithelial Ovarian Cancer
Fang Fang et al.
CANCER (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)
Gregory A. Otterson et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Epigenetic modifications as therapeutic targets
Theresa K. Kelly et al.
NATURE BIOTECHNOLOGY (2010)
Epigenetic modifications and human disease
Anna Portela et al.
NATURE BIOTECHNOLOGY (2010)
DNA methylation and gene expression
Zahava Siegfried et al.
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE (2010)
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors
Lisa A. Cowan et al.
EPIGENOMICS (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
Global Levels of Histone Modifications Predict Prognosis in Different Cancers
David B. Seligson et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Vorinostat in Advanced Prostate Cancer Patients Progressing on Prior Chemotherapy (National Cancer Institute Trial 6862) Trial Results and Interleukin-6 Analysis: A study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium
Deborah Bradley et al.
CANCER (2009)
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)
Robert P. Whitehead et al.
INVESTIGATIONAL NEW DRUGS (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer A Wisconsin Oncology Network Phase II Study
Anne M. Traynor et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Long non-coding RNAs: insights into functions
Tim R. Mercer et al.
NATURE REVIEWS GENETICS (2009)
Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions
J. Wen et al.
ONCOGENE (2009)
Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
A. Francesca Setiadi et al.
CANCER RESEARCH (2008)
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Susan C. Modesitt et al.
GYNECOLOGIC ONCOLOGY (2008)
Molecular origins of cancer: Epigenetics in cancer
Manel Esteller
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Alterations of DNA methylation and clinicopathological diversity of human cancers
Yae Kanai
PATHOLOGY INTERNATIONAL (2008)
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
Omar Khan et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer
George R. Blumenschein et al.
INVESTIGATIONAL NEW DRUGS (2008)
Molecular basis for estrogen receptor α deficiency in BRCA1-linked breast cancer
Alison M. Hosey et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Vorinostat in cutaneous T-CELL lymphoma
Madeleine Duvic et al.
DRUGS OF TODAY (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of epigenetic inheritance
Cyrus Martin et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
Synthetic lethal screen identification of chemosensitizer loci in cancer cells
Angelique W. Whitehurst et al.
NATURE (2007)
Chromatin modifications and their function
Tony Kouzarides
CELL (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer
Guoren Deng et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer
Walter M. Stadler et al.
CLINICAL GENITOURINARY CANCER (2006)
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy
JK Christman
ONCOGENE (2002)
Share Paper
